Company / Financials
Atara Biotherapeutics, Inc. Financials
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$120.8M
FY2025 · +1308.7% YoY
Net Income
$32.7M
FY2025 · +111.8% YoY
Profit Margin
27.1%
FY2025 · net income / revenue
ROE
-
FY2025 · return on equity
Total Assets
$20.2M
FY2025
Total Debt
-
FY2025
Equity
-$38.5M
FY2025
ROA
161.5%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -73.54 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$120.8M+1308.7% YoYNet Income HistoryProfit after all expenses and taxes$32.7M+111.8% YoYOperating Income HistoryProfit from core business operations before interest and taxes$35.9M+113.0% YoYSG&A Expense HistorySelling, general, and administrative expenses$26.3M-48.4% YoYR&D Expense HistoryResearch and development spending$37.4M-83.3% YoYInterest Expense HistoryCost of borrowing and debt obligations$3.8M-28.2% YoYIncome Tax HistoryTotal income tax expense$31.0K+106.7% YoYEPS (Basic) HistoryBasic earnings per share-$11.41+82.5% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$11.41+82.5% YoYShares Outstanding HistoryWeighted average diluted shares outstanding5.9M+37.6% YoY